TuHURA Biosciences (HURA) AI Stock Analysis

• Market Cap: $132.20M
• Dividend Yield: N/A
• Average Volume (3M): 382.82K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.39
• Revenue Growth: N/A
• EPS Growth: 77.12%
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 46,548,565
• 10 Day Avg. Volume: 275,372
• 30 Day Avg. Volume: 382,823
• PEG Ratio: <0.01
• Price to Book (P/B): 0.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.00
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -6.43K
• Enterprise Value/Ebitda: -2.19
• 1Y Price Target: $12.00
• Price Target Upside: 322.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 36 Underperform
• Price Target: ―

TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company's poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.

Positive Factors

Clinical Trials

The initiation of the Phase 3 accelerated approval trial of IFx-2.0 in patients with advanced or metastatic Merkel cell carcinoma is a significant step forward for Tuhura Biosciences.

Financial Health

Tuhura Biosciences announced it entered into an equity financing that should bring in an aggregate $12.5M in capital, combined with $3M raised from warrant exercises and $12.4M in cash, providing financial runway into the first half of 2026.

Mergers and Acquisitions

Upon the completion of the merger with Kineta, Tuhura Biosciences will gain full rights to Kineta's novel VISTA-targeted monoclonal antibody, expanding its therapeutic pipeline.

Negative Factors

Clinical Risks

Risks include negative clinical results with IFx-2.0 and delays in advancing pipeline candidates into registrational programs.

Competitive Risks

There are competitive risks, especially with respect to other checkpoint inhibitors, which could impact Tuhura Biosciences' market position.

Regulatory Risks

Inability to obtain regulatory approvals in a timely manner or at all is a significant risk.

TuHURA Biosciences Business Overview & Revenue Model

Company Description

TuHURA Biosciences (HURA) is a biotechnology company focused on the development and commercialization of innovative therapeutics and diagnostics in the field of personalized medicine. The company operates primarily in the pharmaceutical and healthcare sectors, leveraging cutting-edge genomic technologies to create targeted treatment solutions. Its core products include proprietary diagnostic tests and personalized therapeutic interventions aimed at improving patient outcomes across various disease areas.

How the Company Makes Money

TuHURA Biosciences generates revenue through multiple streams, primarily from the sale of its diagnostic tests and personalized therapeutic products. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to integrate its solutions into clinical settings, driving adoption and sales. Additionally, TuHURA may enter into licensing agreements and strategic partnerships to commercialize its technologies, expanding its market reach and generating royalties. Grants and funding from research initiatives may also contribute to the company's earnings, supporting its ongoing research and development efforts.

TuHURA Biosciences Financial Statement Overview

Summary

TuHURA Biosciences is facing severe financial challenges, with no revenue generation and increasing net losses. The balance sheet reflects significant financial instability, and cash flow statements indicate ongoing cash burn problems. The company appears to be heavily reliant on external financing to maintain operations, posing substantial risks to its long-term viability.

Income Statement

TuHURA Biosciences has consistently reported zero revenue, indicating challenges in commercializing its products or services. The company faces increasing net losses, with a substantial net profit margin decline. The negative EBIT and EBITDA margins highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet reveals a troubling negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not calculable due to negative equity, but high liabilities relative to assets suggest significant leverage. The equity ratio is negative, further emphasizing financial distress.

Cash Flow

Cash flow analysis shows negative operating and free cash flows over time, highlighting cash burn issues. The company is not generating sufficient cash from operations to sustain itself, relying heavily on financing activities for liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Jun 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-116.71K	0.00	0.00	0.00	-32.00K
EBITDA	-17.43M	-29.12M	-9.56M	-6.01M	-38.15M
Net Income	-21.68M	-29.32M	-9.37M	-7.02M	-38.30M
Balance Sheet
Total Assets	19.97M	4.36M	15.20M	6.40M	13.54M
Cash, Cash Equivalents and Short-Term Investments	12.66M	3.67M	14.25M	5.55M	10.54M
Total Debt	202.54K	2.34M	138.22K	644.07K	0.00
Total Liabilities	5.37M	5.92M	2.89M	7.15M	2.96M
Stockholders Equity	14.59M	-1.56M	12.30M	-747.82K	10.58M
Cash Flow
Free Cash Flow	-14.79M	-12.03M	-7.54M	-6.57M	-18.87M
Operating Cash Flow	-14.73M	-11.95M	-7.51M	-6.56M	-18.86M
Investing Cash Flow	-6.05M	-1.30M	-36.28K	-3.28K	964.00K
Financing Cash Flow	29.77M	2.66M	16.25M	7.04M	26.04M

TuHURA Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.84
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HURA, the sentiment is Neutral. The current price of 2.84 is above the 20-day moving average (MA) of 2.51, above the 50-day MA of 2.77, and below the 200-day MA of 3.95, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.87 is Neutral, neither overbought nor oversold. The STOCH value of 89.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HURA.

TuHURA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	62 Neutral	$123.39M	36.90	10.42%	―	0.18%	-55.15%
Sector *	60 Neutral	HK$17.07B	6.10	-7.44%	2.88%	11.55%	-28.15%
LXRX	59 Neutral	$410.39M	―	-86.09%	―	1250.63%	37.24%
DBVT	54 Neutral	$272.90M	―	-198.47%	―	―	-38.86%
TERN	45 Neutral	$529.27M	―	-32.12%	―	―	10.98%
HURA	36 Underperform	$132.20M	―	-244.16%	―	―	77.12%
GOSS	35 Underperform	$404.60M	―	-500.57%	―	―	81.94%

TuHURA Biosciences Corporate Events

TuHURA Biosciences Announces Acquisition of Kineta, Inc.

On March 18, 2025, TuHURA Biosciences announced its intention to acquire Kineta, Inc., which will enhance its product pipeline with Kineta’s VISTA-101 development program. The merger is expected to bring significant synergies and strengthen TuHURA’s position in the biopharmaceutical sector, although it involves various risks and uncertainties related to regulatory approvals and market conditions.

TuHURA Biosciences Expands Board with New Appointment

On March 10, 2025, TuHURA Biosciences appointed Dr. Craig Tendler to its Board of Directors, expanding the board to six members. Dr. Tendler brings extensive experience from his previous role at Johnson & Johnson, where he oversaw major drug approvals and FDA breakthrough designations in oncology. His expertise is expected to aid TuHURA in advancing its drug development programs and evaluating potential collaborations and acquisitions, particularly as the company prepares for a Phase 3 trial of its drug candidate IFx-2.0.